press releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun 11, 2014	Alder BioPharmaceuticals to Present at Two Conferences in June	View HTML Alder BioPharmaceuticals to Present at Two Conferences in June 16.1 KB
Toggle SummaryJun 18, 2014	Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results	View HTML Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results 20.6 KB
Toggle SummaryJun 26, 2014	Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society	View HTML Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society 17.8 KB
Toggle SummaryJun 27, 2014	Alder BioPharmaceuticals Added to Russell 3000(R) Index	View HTML Alder BioPharmaceuticals Added to Russell 3000(R) Index 14.5 KB
Toggle SummaryJul 29, 2014	Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results	View HTML Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results 14 KB
Toggle SummaryAug 05, 2014	Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results Management to Host Conference Call Today at 5:00pm EDT	View HTML Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results 25.9 KB
Toggle SummarySep 02, 2014	Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab	View HTML Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab 20.9 KB
Toggle SummaryOct 06, 2014	Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine	View HTML Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine 19.5 KB
Toggle SummaryOct 24, 2014	Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results	View HTML Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results 14.2 KB
Toggle SummaryNov 03, 2014	Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine ALD403 Targets Well-Validated Biology Through Inhibition of Calcitonin Gene-Related Peptide (CGRP)	View HTML Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine 26.7 KB